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Abstract
Conditional deletion of Apc in the murine intestine alters crypt-villus architecture and function. This process is accompanied
by multiple changes in gene expression, including upregulation of Cited1, whose role in colorectal carcinogenesis is
unknown. Here we explore the relevance of Cited1 to intestinal tumorigenesis. We crossed Cited1 null mice with ApcMin/+
and AhCre+Apcfl/fl mice and determined the impact of Cited1 deficiency on tumour growth/initiation including tumour
multiplicity, cell proliferation, apoptosis and the transcriptome. We show that Cited1 is up-regulated in both human and
murine tumours, and that constitutive deficiency of Cited1 increases survival in ApcMin/+ mice from 230.5 to 515 days.
However, paradoxically, Cited1 deficiency accentuated nearly all aspects of the immediate phenotype 4 days after
conditional deletion of Apc, including an increase in cell death and enhanced perturbation of differentiation, including of
the stem cell compartment. Transcriptome analysis revealed multiple pathway changes, including p53, PI3K and Wnt. The
activation of Wnt through Cited1 deficiency correlated with increased transcription of b-catenin and increased levels of
dephosphorylated b-catenin. Hence, immediately following deletion of Apc, Cited1 normally restrains the Wnt pathway at
the level of b-catenin. Thus deficiency of Cited1 leads to hyper-activation of Wnt signaling and an exaggerated Wnt
phenotype including elevated cell death. Cited1 deficiency decreases intestinal tumourigenesis in ApcMin/+ mice and impacts
upon a number of oncogenic signaling pathways, including Wnt. This restraint imposed by Cited1 is consistent with a
requirement for Cited1 to constrain Wnt activity to a level commensurate with optimal adenoma formation and
maintenance, and provides one mechanism for tumour repression in the absence of Cited1.
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Introduction
Inactivation of the APC (adenomatous polyposis coli) gene
marks one of the earliest events in colorectal tumourigenesis [1],
an observation that has given rise to the concept of Apc as a
‘cellular gatekeeper’ protecting against tumourigenesis [2]. This
role in suppressing tumour formation has been closely associated
with its ability to regulate the level of b-catenin within cells. Thus,
Apc normally forms part of the scaffold of proteins that
phosphorylate b-catenin and target it for degradation. In the
absence of Apc, b-catenin levels become elevated and translocates
to the nucleus, where it drives increased transcription of Wnt
target genes associated with cell proliferation and cell death [3].
To investigate the biological consequences of Apc loss and Wnt
activation, we and others have previously used a conditional model
of Apc loss. In this model, deletion of Apc is achieved through use of
an inducible AhCre transgene, which is responsive to exposure to
the xenobiotic b-napthoflavone. Following Cre induction and loss
of function of Apc, we observe a range of rapid phenotypic
changes. These include promiscuous entry of cells into S phase,
loss of differentiated cell types, loss of cell polarity and
disorganisation of the crypt-villus structure to the point that
discrete crypts are no longer discernable. Apc deficiency also
reduces the normal migration of cells along the crypt villus axis,
leading to the preferential retention of Apc deficient cells. These
changes may all be considered pro-tumourigenic, however we also
observe a considerable stress signal within Apc deficient cells, most
clearly shown by a significant elevation in apoptosis. These
phenotypic changes are accompanied by the expected elevation in
levels of nuclear b-catenin and marked changes in the transcrip-
tome [3].
One of the changes we observe in the intestinal epithelial cells
of AhCre+Apcfl/fl mice is a strong induction of Cited1, a bi-
functional transcriptional cofactor which is able to activate or
repress transcription in association with other transcription
factors [4,5]. We also found this induction to be dependent
upon functional c-Myc as Cited1 expression returns to basal
levels in the additional absence of c-Myc, which completely
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rescues the phenotype of Apc deficiency [6]. These observations
suggest that elevation of Cited1 may be directly associated with
the preneoplastic phenotype.
Cited1 was originally identified in a mouse melanoma cell line
[7]. During vertebrate development, Cited1 is expressed in
progenitors of the heart, limb, axial skeleton, kidney, and placenta
[8,9]. It is implicated as a key co-ordinator during renal epithelial
morphogenesis [5] and is involved in mammary gland develop-
ment [10]. Cited1 is required for placental development with effect
on embryo growth and survival [9]. However, Cited1 null mice
that survive the early postnatal period are otherwise grossly
phenotypically normal [9]. Cited1 is also able to enhance TGF-b
signaling and inhibit Wnt signaling depending on cellular context
[5,11]. Both activation and inhibition of transcription are
dependent on the CBP/p300 binding C-terminal transcription
activation domain CR2, which is conserved throughout the Cited
family [5,11–13].
Deregulation of CITED1 has been implicated in several human
cancers, including melanomas, Wilm’s tumours and nephroblas-
tomas [7,14–16]. In the mouse, Cited1 is up-regulated in MMTV-
Cre/FloxNeoNeuNT mammary tumours and associates with the
transcription factor EGR2 to regulate the expression of the
oncogene ErbB2 (HER2, Neu) [17]. Recently it has been shown
that Cited1 expression, together with another transcription
regulator Six2, specify self-renewing nephron progenitor cells in
kidney development and it is suggested that Cited proteins may
contribute to the maintenance of the self-renewing capping
mesenchyme in the developing kidney [18–20]. Thus, although
a body of studies have implicated Cited1 in both embryogenesis
and carcinogenesis, its potential role in Wnt-induced intestinal
tumourigenesis remains unresolved.
Given the data implicating Cited1 as a regulator of the Wnt
pathway, we have tested the hypothesis that Cited1 plays a key role
in intestinal tumourigenesis. We show that CITED1 is upregulated
in human colorectal cancers and that Cited1 deficiency increases
the survival of ApcMin/+ mice. When crossed into our acute model
of Apc deficiency, we show that loss of Cited1 accentuates nearly all
aspects of the Apc deficient phenotype, including the transcription
of a range of oncogenic signaling pathways, including the Wnt
pathway.
Results
Cited1/CITED1 is up-regulated in the intestine of Apc
deficient mouse models and human colorectal tumours
We have previously shown that deletion of Apc in the mouse
intestine leads to nuclear b-catenin translocation and up-regula-
tion of Wnt target genes, including Cited1, as scored by microarray
analysis [3]. To confirm this upregulation, we analysed mouse
intestinal epithelium from AhCre+Apcfl/fl and AhCre+WT (WT: wild
type) mice which had been induced by intraperitoneal injection of
b-napthoflavone 4 days previously [3]. Quantitative PCR analysis
revealed significant upregulation of the Wnt targets c-Myc, Axin2
and Cd44 in the absence of Apc. Similarly, Cited1 showed a 15-fold
increase in expression (p,0.05, Figure 1A).
To determine if CITED1 was also deregulated in human
cancers, we performed a Taqman quantitative PCR on human
colorectal tumour tissues. In comparison to paired normal tissues
from the same patient, we observed over-expression of the human
orthologues of the Wnt target genes c-MYC, AXIN2, CD44 and
CITED1 (p,0.01, Figure 1B). These data demonstrate the
potential transferability of our data from the acute Apc deletion
mouse model to human colorectal carcinogenesis.
We next assessed Cited1 levels in adenomas developing in the
ApcMin/+ mouse model of human colorectal cancer, which allows
evaluation of the effects of loss of Apc function over the course of
polyp development. Again, the level of Cited1 expression was
significantly increased in intestinal polyps from ApcMin/+ mice
compared to normal tissue from the same mouse (p,0.01,
Figure 1C; Figure S1A). Detection of high levels of Cited1/
CITED1 expression in both human and murine tumours suggests
that Cited1/CITED1 may play a role in intestinal tumourigenesis.
We performed in situ hybridization using a Cited1 probe
designed against the deleted sequence in the Cited12 mouse
(Figure 1D). We observed low levels of staining (compared to
expression of the housekeeping gene Polr2a) throughout the crypt-
villus structure in the AhCre+WT mouse intestine (WT) with a trend
to higher levels within the crypt. There was no apparent specificity
for the stem cell region at the base of the crypt or for any
differentiated cell type. Consistent with QPCR data, we observed
an increase in the level of staining throughout the crypt-villus
structure of the AhCre+Apcfl/fl mouse.
Loss of Cited1 in ApcMin/+ mice increases survival and
reduces the number of intestinal adenomas
As Cited1 is upregulated in colonic tumors we next asked
whether deficiency of Cited1 could inhibit intestinal adenoma
formation in the ApcMin/+ mouse. To achieve this, we crossed
Cited1 null (Cited12) mice onto ApcMin/+. Given that Cited1 is on the
X-chromosome, we aged male cohorts of ApcMin/+Cited12 and
ApcMin/+ mice until they displayed symptoms of intestinal neoplasia
(rectal bleeding and paling feet). The median lifespan of ApcMin/+
mice was 230.5 days, which is increased to 515 days in the ApcMin/+
Cited12 mice (Log-Rank p= 0.001, Figure 2A). Cited12 mice had a
survival rate that was not significantly different to that of WT mice
(Figure 2A).
We next counted the number of adenomas in the small and
large intestine (Figure 2B). ApcMin/+Cited12 mice developed
significantly less tumours compared to ApcMin/+ in both the small
intestine (5 versus 18.5 adenomas p,0.05) and the large intestine
(1 versus 6.5 adenomas, p,0.05). The tumour distribution in the
small intestine and the colon was analysed at ill health (Figure
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(MinCited1). We observed that MinCited1 mice developed
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suggesting that Cited1 is pro-tumourigenic. However, we
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deregulation of the Wnt pathway and cell death. To
explain this apparent paradox, we propose a model
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Figure 1. Cited1 over-expression in ApcMin/+mice, AhCre+Apcfl/fl mice and human colorectal cancer. A: QPCR analysis of Wnt target genes 4
days after conditional deletion of Apc in the small intestinal. * p,0.05, Mann-Whitney U test, n = 3. B: Taqman qPCR analysis of gene expression in
human CRC tumour tissue presented as fold change relative to adjacent normal tissue. The horizontal line indicates median fold change. p,0.01,
Wilcoxon Signed Rank Test. C: Semi-QPCR analysis of Cited1 expression in ApcMin/+ adenomas. Three ApcMin/+ mice were used and 3–6 tumours were
taken from each individual, n = 14. (p,0.01, Mann-Whitney U test). D: Cited1 in situ hybridization showing the increase in Cited1 expression in the
AhCre+Apcfl/fl compare to AhCre+WT mouse. The staining is represented by single dots which correspond to the Cited1 transcript. The low level of
staining (compared to positive control probe Polr2a) of Cited1 probe is distributed throughout the crypt-villus structure in the AhCre+WT mouse and
in AhCre+Apcfl/fl mouse with an increase in staining after loss of Apc. Absence of staining is observed in the Cited12 intestinal tissue and in the
negative control probe DapB. Inset panels show magnifications of intestine of corresponding zone.
doi:10.1371/journal.pgen.1003638.g001
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S1C). There was no significant difference in the percentage of
tumours found in the duodenum or jejunum of the small intestine,
or in the large intestine. However, we did observe a significant
increase in the percentage of tumours found in the last part of the
small intestine which corresponds to the human ileum (Figure
S1C). Total tumour burden of ApcMin/+Cited12 mice was not
significantly different from that of ApcMin/+ (Figure 2C), and shared
the same tubular morphology and degree of invasiveness, as
assessed histologically by the frequency of invasion into the
submucosa (52.8% High grade +47.16% Low grade in ApcMin/+ vs
42.8% High grade +57.4% Low grade in ApcMin/+Cited12, Chi-
square x2 = 2.1, DF= 1, p.0.05). These data suggest that mice
became symptomatic of disease when they had developed an
equivalent tumour burden, but that in the Cited1 mutant
background this was significantly later and reflected fewer, but
larger lesions at these later time points, hence implicating Cited1
in intestinal tumour initiation.
Cited1 deficiency modifies the phenotype observed
immediately after Apc loss by increasing the number of
Brdu positive cells and the size of the hyperplastic area
To address the mechanism underlying the reduction of
adenoma formation in ApcMin/+Cited12 mice, we crossed Cited12
mice with mice conditionally mutant for Apc. We have previously
demonstrated that we can achieve almost 100% recombination of
the Apcfl/fl allele in the intestine using the b-napthoflavone
inducible AhCre transgene to drive recombination [3]. Thus,
AhCre+WT, AhCre+Apcfl/fl, AhCre+Cited12, and AhCre+Apcfl/flCited12
mice were induced with b-napthoflavone and culled 4 days after
the first injection to determine the role of Cited1 immediately
following deletion of Apc. To confirm the level of Apcfl/fl
recombination we used quantitative RT-PCR and again found
that 100% of the PCR products obtained were from the
recombined Apc allele (Figure S1B). We also confirmed Cited1
deficiency in Cited12 mice using RT-PCR. We observed a
significant 3.81 fold difference decrease in Cited1 expression in
AhCre+Cited12 compare to AhCre+WT. The small difference
observed is most likely due to the low level of expression of
Cited1 in the intestine [21]. Due to the increased level of Cited1
expression after loss of Apc, Cited1 deficiency is more noticeable in
the intestinal epithelial cells of AhCre+Apcfl/flCited12 mice which
showed a 277.81 fold decrease compared to AhCre+Apcfl/fl mice
(p,0.05 Mann-Whitney U test).
We have previously shown that the loss of Apc leads to an increase
in proliferation and apoptosis and also to a loss of migration [3]. To
analyse the effects of Cited1 deficiency after Apc loss, we first counted
Figure 2. Loss of Cited1 extends lifespan of ApcMin/+ mice and reduces the number of intestinal adenomas. A: Kaplan-Meier plot of
survival of ApcMin/+ (thin continuous line), ApcMin/+Cited12 mice (thick continuous line), Cited12 (dashed line) and WT (dotted line). The median
lifespan of ApcMin/+ mice cohort was 230.5 days (n = 8), which was increased to 515 days in ApcMin/+Cited12 mice (n = 5) (p = 0.001 Log-Rank test). The
median lifespan of Cited12 was 766 days (n = 10) and is similar to WT with a lifespan of 760 days (n = 12) (p = 0.749 Log-Rank test). B: In both small
intestine (grey boxes) and large intestine (blank boxes), tumour numbers were reduced in ApcMin/+Cited12 mice (n = 5) compared to ApcMin/+ mice
(n = 8) (*p,0.05, Mann-Whitney U test). C: Tumour burden was calculated and represent the total tumour volume per mouse. There is no significant
difference between ApcMin/+ (white) and ApcMin/+Cited12 (Grey) (p.0.05, Mann-Whitney U test).
doi:10.1371/journal.pgen.1003638.g002
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the number of cells in S phase within the crypt or hyperplastic areas
(formed after Apc loss). On day 4 after b-napthoflavone induction,
mice were injected with BrdU to label cells in S-phase and culled
2 hrs later (Figure 3A). In AhCre+WT and AhCre+Cited12 mice the
number of proliferating cells was not significantly different
(AhCre+WT: 18.97 vs AhCre+Cited12: 20.65 BrdU positive cells/
Crypt; p.0.05. Figure 3B). However, the number of cells in S-phase
was significantly increased in the hyperplastic areas of AhCre+Apcfl/fl
Cited12mice compared to AhCre+Apcfl/flmice (AhCre+Apcfl/fl: 74.13 vs
AhCre+Apcfl/flCited12: 106.4 BrdU positive cells/area, p,0.05,
Figure 3B) suggesting a role for Cited1 in controlling cell proliferation
in the context of active Wnt signaling.
We next analysed the histology on HE sections of the intestinal
tissue from all the genotypes after b-napthoflavone induction.
There were no gross changes in the crypt/villus architecture in
AhCre+WT compared to AhCre+Cited12 mice, and induced
AhCre+Apcfl/flCited12 mice had similar large aberrant crypts to
those observed in AhCre+Apcfl/fl mice (Figure 4D).
Given our findings of decreased adenoma formation in ApcMin/+
mice, we also examined the extent of the hyperplastic area within
the crypts of AhCre+Apcfl/fl mice compared to AhCre+Apcfl/flCited12
mice as determined by the extent of BrdU labelling. Surprisingly,
the number of cells in the hyperplastic area was greater in
AhCre+Apcfl/flCited12 mice compared to AhCre+Apcfl/fl mice (Ah-
Cre+Apcfl/fl: 78 cells/area vs AhCre+Apcfl/flCited12 :106 cells/area,
p,0.05, Figure 4E).
We next determined migration rates by comparing the position
of cells 2 hrs and 24 hrs after BrdU labelling. The difference
between the 2 hrs and 24 hrs distributions for a genotype was
analysed with the Kolmogorov–Smirnov test. The distribution of
Brdu positive cells from 2 hrs to 24 hrs varies significantly for all
genotypes (p = 0.01) indicating cell migration. Enterocytes in
AhCre+WT mice and AhCre+Cited12 mice migrate at the same rate
(20 cell positions at the 50% cumulative frequency) whereas cells in
both AhCre+Apcfl/fl mice and AhCre+Apcfl/flCited12 mice show greatly
reduced migration rates (Figure 3C). Critically, although deletion
of Apc in AhCre+Apcfl/fl mice results in strong suppression of
migration (9 cell position migration), some movement of cells was
detected in these samples (Figure 3C). By comparison, the absence
of Cited1 in AhCre+Apcfl/flCited12 mice, resulted in even less
migration (2 cell position migration) than observed for enterocytes
in AhCre+Apcfl/fl mice (Figure 3C). Together, these data demon-
strate that Cited1 deficiency further exacerbates both the prolifer-
ation and migration phenotypes of Apc loss in the intestine, which
is surprising given that ApcMin/+Cited12 mice developed signifi-
cantly less intestinal tumours than ApcMin/+mice. Consistent with
these observations that proliferation is increased in AhCre+Apcfl/
flCited12 mice, we also observed a decrease in the number of
differentiated entoendocrine cells and goblet cells in these mice
(Figure S5A–D).
We and others have previously demonstrated that the location
and the number of paneth cells in the intestinal crypt are regulated
by Wnt signalling [6,22–24]. It is observed by the increased
number of paneth cells after loss of Apc (Figure S5F) and the loss
of positioning at the bottom of the crypt (Figure S5E–G).
Consistent with our observations that the phenotype of Ah-
Cre+Apcfl/fl mice is enhanced upon deficiency of Cited1 we also
observe a change in position of the paneth cells in the hyperplastic
areas of the AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl (Figure
S5G). This is most likely due to the increase in crypt size seen in
the double mutant, which gives cells a bigger area to be
distributed.
Cited1 deficiency enhances the apoptotic phenotype
observed immediately after Apc loss
The increase in proliferation observed in the intestine following
deletion of Apc is also associated with a dramatic increase in
apoptosis [3]. We therefore examined if Cited1 was regulating
apoptosis by counting apoptotic bodies in H&E sections and also
scoring Caspase 3 staining. We observed no significant difference
in apoptosis between AhCre+WT and AhCre+Cited12 mice, however,
there was a significant increase in the number of apoptotic cells in
AhCre+Apcfl/flCited12 mice compared to AhCre+Apcfl/fl mice, which
was verified by both methods (Figure 4A).
As mentioned above, we observed an increase in the number of
cells per hyperplastic area in the AhCre+Apcfl/flCited12 samples. To
verify that the increase in cell death was not an artefact of the
difference in the number of cells per area, we corrected for this
difference between AhCre+Apcfl/fl and AhCre+Apcfl/flCited12 mice. The
normalised data confirmed increased cell death in AhCre+Apcfl/fl
Cited12 compared to AhCre+Apcfl/fl (p,0.05) after H&E counting
(AhCre+Apcfl/fl : 11.53 apoptotic cells/area vs AhCre+Apcfl/
flCited12: 15.33 apoptotic cells/area, p,0.05) and after anti
cleaved-Caspase3 staining (AhCre+Apcfl/fl: 7.32 apoptotic cells/
area vs AhCre+Apcfl/flCited12: 9.53 apoptotic cells/area, p,0.05)
(Figure 4B–C). These data indicate that the increase in cell
death is not proportional to the increase in cell proliferation.
Therefore, Cited1 deficiency in a Wnt perturbed background
accentuates the apoptotic response.
Scoring of Caspase3 positive cells revealed no change in the
number of apoptotic cells in the intestinal tumors of ApcMin/
+Cited12 mice compared to ApcMin/+ mice at time of
death (Figure 4F). Therefore, the increased apoptosis we
observe in the absence of Cited1 is only manifested in the
context of acute Wnt activation, which underlines the role of
Cited1 in restraining tumour initiation, and also implies that
in those tumours that do develop in the absence of Cited1,
they have developed alternate mechanisms to restrain the
Wnt pathway.
Figure 3. Cited1 deficiency increases enterocyte proliferation and decreased cell migration in AhCre+Apcfl/fl mice. A: Cell proliferation
assessed by IHC (immunohistochemistry) in AhCre+WT (WT), AhCre+Cited12, (Cited12) AhCre+Apcfl/fl(Apcfl/fl) and AhCre+Apcfl/flCited12(Apcfl/flCited12)
mice. Bottom panels show magnifications of intestine of corresponding zone. B: Histograms showing the number of BrdU positive cells/crypt or
hyperplastic areas. No significant difference in the localisation or number of BrdU positive cells between AhCre+WT and AhCre+Cited12 (p = 0.6625).
Significant increase in the number of BrdU positive cell in AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl (*p = 0.0404). C: Graphs showing the
position of BrdU positive cells after 2 hrs (solid line) and 24 hrs (dashed line). The cumulative frequency represents the percentage of BrdU positive
cells at a particular position from the bottom of the crypt or hyperplastic areas to the tip of the villus. The difference between the 2 hrs and 24 hrs
distributions for a genotype was analysed with the Kolmogorov–Smirnov test. The distribution of Brdu positive cells from 2 hrs to 24 hrs varies
significantly for all genotypes (p = 0.01) indicating cell migration. The migration of cells from 2 hrs to 24 hrs after Brdu labelling is similar in AhCre+WT
compared to AhCre+Cited12 as shown by the distance between the 2 distributions (20 cell positions at the 50% cumulative frequency). In AhCre+Apcfl/fl,
the distance is reduced to 9 cell positions indicating reduced migration compared to AhCre+WT (20 positions) and AhCre+Cited12 (20 positions). The
migration is further reduced in AhCre+Apcfl/flCited12 as the 50% cumulative frequency position moved only 2 positions, compared to AhCre+Apcfl/fl (9
positions). *p,0.05; Statistical tests were done using Mann-Whitney U test (B) or Kolmogorov–Smirnov test (C); NS Non significant. (N= 3/genotype).
doi:10.1371/journal.pgen.1003638.g003
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Cited 1 regulates several pathways including the Wnt
signaling pathway
We next wished to investigate the mechanism through which
Cited1 may be modifying Wnt driven tumorigenesis. One
possibility is a direct effect upon Wnt signaling, and in support
of this, Cited1 has previously been shown to be able to bind to b-
catenin and consequently inhibit Wnt induced transcription
during Xenopus development [5]. Two potential TCF-4 sites were
identified in the Cited1 promoter region (ctttgt and cattgaa in the
2 kb prior exon1). This implicates Cited1 in the control of the Wnt
pathway, however this is not the only pathway known to be altered
by Cited1. Cited1 has been shown to bind to the p300/CBP
coactivators and also to Smad4, thereby enhancing their
transcriptional activity [11,25]. To analyse the effects of Cited1
deficiency on various transcriptional pathways we performed a
microarray analysis using the Affimetrix Chip 430 2.0 and
AffylmGUI software [26]. We then submitted our microarray
data to ingenuity pathway analysis software (IPA) to identify
pathways significantly affected by Cited1 deficiency.
In the AhCre+WT after additional loss of Cited1, a number of
signaling pathways identified by IPA analysis were found to be
affected, amongst them: P53 (p= 6.8761026, ratio = 0.146),
PI3K/AKT (p= 6.7461026, ratio = 0.114), Pten (p = 7.761024,
ratio = 0.097); Wnt (p = 1.0861021, ratio = 0.057); and TGFb
(p.0.1, ratio = 0.034). Several targets were analysed by QPCR
including c-Myc, Axin2, CD44, Sox4, p53, Pten, Akt1, and Smad4 but
none were found to be significantly deregulated (N= 6, p.0.05;
Mann-Whitney).
Several signaling pathways identified by IPA analysis were
affected in AhCre+Apcfl/flCited12 mice compared to AhCre+Apcfl/fl
mice, including: P53 (p = 3.561028, ratio = 0.177); PI3K/AKT
(p= 2.6261025, ratio = 0.107); Pten (p= 7.2261024, ra-
tio = 0.097), Wnt (p= 5.461022, ratio = 0.063); and TGFb
(p = 2.2261021, ratio 0.056). The validity of the IPA analysis
was subsequently verified by QPCR. We analysed several targets
from these pathways by QPCR, and found significant upregula-
tion of p53, Runx1, Sox4 (Figure S2C) and a number of Wnt targets
known to be deregulated in the intestines of AhCre+Apcfl/fl mice [3]
or listed as Wnt target genes in the Nusse webpage (http://www.
stanford.edu/group/nusselab/cgi-bin/wnt/target_genes) (Figure
5A–B). 10 Wnt target genes, including c-Myc, Axin2, and CD44
were confirmed by QPCR to be significantly up-regulated in
AhCre+Apcfl/flCited12 mice compared to AhCre+Apcfl/fl mice
(Figure 5A). Three additional transcripts were analysed by
microarray analysis that have previously been identified as key
players in the Wnt pathway (Nucleophosmin, Nucleolin, and
b-catenin respectively: [27–29]). These were also found to be
upregulated in AhCre+Apcfl/flCited12 mice compared to AhCre+Apcfl/fl
mice. These data indicate that Cited1 inhibits several signaling
pathways, including the Wnt pathway following Apc loss.
Stem cell markers are upregulated after loss of Cited1
The Wnt signalling pathway has been shown to play a critical
role in intestinal homeostasis which includes stem cells mainte-
nance. Because Cited1 loss leads to a deregulation of the Wnt
pathway and due to the potential role of Cited1 in the stem cell
niche in the cap mesemchyme in the developing kidney [18], we
analysed the effect of Cited1 deficiency in the intestine. RT-QPCR
analysis revealed a significant upregulation of several stem cell
markers (Gpr49, Ascl2, Musashi and Olfm4) in AhCre+Apcfl/flCited12
tissues compared to AhCre+Apcfl/fl controls (Figure 5C). We also
performed ISH for the surrogate marker of Lgr5, Olfm4 (Figure 5D).
In AhCre+Wt and AhCre+Cited12 mice the location of Olfm4
expressing cells is confined to the stem cell niche at the base of
the crypts. In AhCre+Apcfl/fl mice, Olfm4 expressing cells were
distributed throughout the hyperplastic area. In AhCre+Apcfl/fl
Cited12 mice Olfm4 expressing cells are also mislocalised through-
out the aberrant crypts but expression is increased, consistent with
our RT-QPCR data of the same tissue (Figure 5C).
Cited1 influences the level of the active form of b-catenin
in the small intestine
Loss of Apc has been shown to drive an increase in total b-
catenin and more importantly a re-localisation of the active form
of b-catenin to the nucleus [3]. To test if Cited1 deficiency modified
this phenotype, we analysed the localisation of total b-catenin in
the small intestine by immuno-histochemistry (Figure 6A). We
observed a normal pattern of localisation in both AhCre+WT and
AhCre+Cited12 mice consistent with previous findings [30]. Upon
deletion of Apc, we observed nuclear translocation of b-catenin in
the aberrant crypts of both AhCre+Apcfl/fl and AhCre+Apcfl/flCited12
mice (Figure 6A) indicative of de-regulated Wnt signalling.
b-catenin regulates important cellular functions such as
transcription and adhesion [31], and the cellular concentration
and phosphorylation status of b-catenin has been shown to impact
on these functions [31,29]. As we observe an increase in the
transcription of several Wnt target genes in AhCre+Apcfl/flCited12
mice we examined the level of total b-catenin, the extent of
phosphorylation at multiple sites and the ratio of transcriptionally
active free b-catenin in purified intestinal epithelial cells (Figure 6B)
as previously described [32]. First, we observed a significant
increase in total b-catenin accompanied by an increase in the
active form of b-catenin (dephosphorylation at pS33, pS37, pT41
sites) in AhCre+Apcfl/fl and AhCre+Apcfl/flCited12 mice compared to
AhCre+WT and very importantly in AhCre+Apcfl/fl mice compared to
AhCre+Apcfl/flCited12 mice.
These data were confirmed by western blot analysis using an
antibody raised against total b-catenin (Figure 6C) or against the
active form of b-catenin (dephosphorylated sites pS33, pS37,
pT41) (Figure 6D) and were verified with a second antibody
against dephosphorylated b-catenin (Figure S2A–B). There was no
Figure 4. Cited1 deficiency enhances increased apoptosis in AhCre+Apcfl/fl mice. A: Histograms showing the levels of apoptosis in each
genotype. Apoptotic cells were scored by H&E staining (left) or cleaved-Caspase3 antibody (right). Both graphs show an increase in the number of
apoptotic cells in AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl (AhCre+Apcfl/fl,AhCre+Apcfl/flCited12, Left: p = 0.0404; Right: p = 0.0259). No
significant difference is observed between AhCre+WT and AhCre+Cited12 (AhCre+WT=AhCre+Cited12, Left: p = 0.1914; right: p = 0.0952). B: The
number of apoptotic cells were normalised to the number of total cells per hyperplastic area in AhCre+Apcfl/fl versus AhCre+Apcfl/flCited12. After
normalisation, the number of apoptotic cells is greater in AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl (H&E: AhCre+Apcfl/fl,AhCre+Apcfl/flCited12,
p = 0.0404; cleaved-Caspase3: AhCre+Apcfl/fl,AhCre+Apcfl/flCited12, p = 0.0259). C: cleaved-Caspase3 representative pictures showing an increase in
apoptotic bodies in AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl. D: Histology by H&E stained mouse intestinal sections in each genotype. Bottom
panels show magnifications of intestine of corresponding zone. E: Scoring of epithelial cells per hyperplastic areas using the extent of BrdU labelling.
Histograms show a significant increase in epithelial cell number in the hyperplastic areas from AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl mice
(p,0.05). *p,0.05; All statistical tests were done using Mann-Whitney U test ; NS Non significant. (n = 3/genotype). F: Histograms showing the levels
of apoptosis (cleaved Caspase 3 antibody) in tumours of ApcMin/+ (white) and ApcMin/+Cited12 mice (Grey). There is no significant difference between
the 2 genotypes (p.0.05, Mann-Whitney U test).
doi:10.1371/journal.pgen.1003638.g004
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significant difference in the phosphorylated (inactive) form of b-
catenin (phosphorylated b-catenin at pS33, pS37, pT41 sites is
degraded as a mechanism of regulating Wnt signalling) between all
genotypes (Figure 6B). b-catenin phosphorylated at pS45 (phos-
phorylated by casein kinase Ia as part of degradation pathway) is
significantly increased in AhCre+Apcfl/flCited12 compared to Ah-
Cre+WT and AhCre+Apcfl/fl.
Given that b-catenin can also be phosphorylated by Protein
Kinase A (PKA) at Ser552 and Ser675 which acts to inhibit
ubiquitination and therefore increase levels of active b-catenin
[33], we also analysed levels of pS552 and pS675 and found
phosphorylation at S675 significantly increased in AhCre+Apcfl/fl
Cited12 tissues compared to AhCre+WT and AhCre+Apcfl/fl, demon-
strating the ability of Cited1 to regulate b-catenin at multiple sites
(Figure 6B).
We also measured the intracellular free b-catenin (active b-
catenin) levels by pull-down with a GST-fusion protein of the
inhibitor of b-catenin and TCF-4 (ICAT). We observed a
significant increase in free b-catenin in AhCre+Apcfl/fl and
AhCre+Apcfl/flCited12 mice compared to AhCre+WT and noticeably
a significant increase in AhCre+Apcfl/flCited12 compared to
AhCre+Apcfl/fl mice (Figure 6B). These data support our findings
above which indicate that Cited1 deficiency increases the levels of
active dephosphorylated b-catenin.
These data demonstrated that the active dephosphorylated form
of b-catenin in purified intestinal epithelial cells is markedly
increased upon Cited1 deficiency. Although the level of dephos-
phorylated b-catenin is increased in Cited12 intestinal cells
compared to WT mice, it is below that observed in the
AhCre+Apcfl/fl intestinal cells (Figure 6B, 6D). As Cited12 mice do
not develop any intestinal phenotypes such as hyperproliferation
this suggests that the level of Wnt activation in Cited12 mice is
below the critical threshold required to induce neoplasia [34].
However, when Apc is deleted in Cited1 deficient mice
(AhCre+Apcfl/flCited12) the level of dephosphorylated b-catenin is
greater than that observed with Apc loss alone, thus providing an
explanation for the increased transcription of Wnt target genes
observed in these mice (Figure 5A).
Discussion
Colorectal cancer is driven by a multiplicity of different
biochemical pathways, however, key amongst these is the Wnt
pathway, which we and others have previously shown to activate a
set of c-Myc dependent genes which are critical for the early stages
of colorectal cancer [6,35]. One of these genes is Cited1, which has
been found to interact at the protein level with b-catenin and
thereby negatively regulate b-catenin transcription [5]. Its
relevance to carcinogenesis has already been described as Cited1
up-regulation has been observed in various cancers [14,36,37].
Here, we have extended those observations and find that CITED1
is significantly up-regulated in colorectal tumours from patients
and in intestinal adenomas developing in the ApcMin/+ mouse
model [38]. We also previously found Cited1 to be over-expressed
in intestinal epithelial cells immediately following deletion of the
Wnt regulator gene Apc in AhCre+Apcfl/fl mice in a c-Myc
dependent manner [6]. These data establish Cited1 as an
immediate Wnt target gene in the intestine.
On the basis of these data we hypothesised that Cited1 might
control b-catenin activity and thereby modulate Wnt signaling
activation and its effects on colorectal tumorigenesis. To investi-
gate this, we used microarray analysis and quantitative PCR
studies to show that loss of Cited1 on an Apc deficient background
does indeed impact upon a range of oncogenic signaling pathways,
including Wnt. Our array data therefore show multiple effects of
Cited1 deficiency including negative regulation of the Wnt-
pathway.
To investigate the requirement of Cited1 during Wnt induced
tumourigenesis, we analysed the effects of deletion of Cited1 in two
well characterised mouse models of Wnt signaling activation; the
ApcMin/+ mouse model of colorectal tumourigenesis and the
AhCre+Apcfl/fl mouse, a conditional model of Apc loss in which the
immediate phenotypic consequences of Apc deletion can be
studied [3]. Surprisingly, we obtained the apparently paradoxical
result that although ApcMin/+Cited12 mice developed fewer
intestinal tumours (associated with an increased life-span) than
ApcMin/+ mice, the phenotypes induced upon conditional loss of
Apc (including perturbed cell proliferation, apoptosis, differenti-
ation and migration) were enhanced, rather than diminished, with
additional loss of Cited1. Of note, we observed reduced capacity to
differentiate (reflected by a reduced number of goblet cells and
enteroendocrine cells), but no difference in total paneth cell
numbers, although we did observe a difference in the positioning
of paneth cells, which may well reflect differences in the Wnt
signalling environment.
Our studies, suggest that a possible explanation for this apparent
paradox is that the hyper-activated Wnt phenotype that occurs in
the absence of Cited1 includes increased apoptosis. Several studies
in cell culture systems already support such a model. For example,
it has been reported that overexpression of b-catenin when
transfected into cell lines leads to a 3–4 fold increase in cell death
[39]. In addition, it has been demonstrated that high levels of c-
Myc induce apoptosis in vivo [40]. This is consistent with our
observations that c-Myc is overexpressed immediately following
deletion of Apc in the intestine and that levels are significantly
increased further with additional absence of Cited1. We interpret
our data to indicate that the increase in apoptosis may counteract
the increase in proliferation to the extent that the overall effect is
reduced development of Wnt transformed cells and consequently
inhibition of tumourigenesis.
The mechanism underlying such hyper-activation of Wnt
signaling appears to be at least in part mediated through increased
levels of dephosphorylated b-catenin, which we found to be up-
regulated in AhCre+Apcfl/flCited12 tissue compared to comparable
AhCre+Apcfl/fl tissue at both the transcriptional and protein levels.
Thus, we found increased levels of the dephosphorylated forms of
b-catenin (T41, S33, S37). These sites when phosphorylated are
involved in the degradation of b-catenin by the proteasome
pathway [31]. This is accompanied by an increase in the levels of
phosphorylation at serine 675 which has been shown to be
phosphorylated by protein kinase A (PKA) and which has been
shown to lead to inhibiting of ubiquitination of b-catenin causing
Figure 5. Expression levels of Wnt target genes after loss of Cited. A: Fold change of Wnt target gene expression in the small intestinal
epithelium of AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl mice measured by QRT-PCR, *p,0.05 Mann Whitney U test. B: Microarray analysis
showing up-regulation of Wnt target genes with Wnt Key players in AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl: Fold changes (FC) are presented
with correspondent P value and B value (B statistic is lod score). C: Fold change of stem cell markers expression in the small intestinal epithelium of
AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl mice measured by QRT-PCR, *p,0.05 Mann Whitney U test. D: In situ Hybridization (ISH) analysis of
Olfm4 in intestinal epithelial cells of all 4 genotypes. Inset panels show magnifications of intestine of corresponding zone.
doi:10.1371/journal.pgen.1003638.g005
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its accumulation and subsequent Wnt signalling activation. We
therefore show that Cited deficiency increases the pool of active b-
catenin, consistent with the enhanced Wnt pathway activation we
observe. It does however remain possible that Cited1 may in
addition be mediating its effects downstream of b-catenin.
We cannot rule out the possibility that the other pathway
changes we observe are responsible for the reduction in
tumourigenesis in ApcMin/+Cited12 mice, as the effects of loss of
Cited1 are not exclusive to the Wnt pathway. We also cannot rule
out that the effects we observe may be secondary to Cited1 deletion.
For example, it is possible that some of the changes we observe
may be due directly to the upregulation of c-Myc rather than a
direct consequence of Cited1 loss. Functional delineation of the
precise relevance of all the changes we observe requires multiple
crosses onto the relevant pathways to probe such dependency.
Finally, AhCre+WT, AhCre+Apcfl/fl, AhCre+Cited12, and AhCre+Apcfl/fl
Cited12 mice were maintained on an outbred background, and
because the comparisons of genotypes within the same littermates
was restricted due to the small number of litter size, we cannot
completely rule out the effect of gene modifiers on the Cited1 loss
phenotype.
Our current primary hypothesis is that Cited1 deficiency
mediates its effects upon adenoma formation primarily through
the apparently paradoxical derepression of the Wnt pathway. This
result is however consistent with a ‘‘just right model’’ wherein a
specific level of Wnt signaling activity is required for maximal
tumour development and those levels of Wnt signaling above or
below this level compromise tumour growth [41]. This model is
further supported by recent studies on a novel mutant Apc mouse
(Apc1322T), which has reduced Wnt signaling compared to ApcMin/+
littermates, but surprisingly develops significantly more intestinal
tumours [42]. Recently it was shown by Leedham et al [43] that in
normal mouse intestine, stem cell markers and Wnt target genes are
expressed in a physiological gradient compatible with normal
intestinal homeostasis. Pathological activation of Wnt activity using
the Ctnnb1Dex3 mouse model led to variable gradients in stem cell
number and Wnt signalling activity which influenced tumour
susceptibility, with regional differences in tumour predisposition
throughout the length of the intestinal tract. This data, which
supports the just right model hypothesis, may explain the variation we
observe in the tumour distribution in the ileum between the ApcMin/+
and ApcMin/+Cited12 mice models. These observations clearly show
that there is not a simple linear relationship between Wnt pathway
activity and tumour burden. Our data is consistent with another
version of this ‘‘just right’’ concept where perturbation of Cited1 leads
to increased dephosphorylated b-catenin and hyper-activation of the
Wnt pathway to a level that is incompatible with maximum tumour
growth (Figure 7). Notably, this relationship appears specific to the
intestine as similar analysis of kidney tumorigenesis in these mice
showed no effect of Cited deficiency (Figure S3). Furthermore, to
define the precise relationship between Wnt levels and tumourigeni-
city will require mouse modelling experiments in which Wnt activity
is precisely regulated at numerous levels.
Wnt/beta-catenin signalling plays a key role in the homeostasis
of the intestinal epithelium and its role in the fate and maintenance
of the stem cell compartment have been clearly demonstrated
[44]. Our data clearly show that Cited1 is an immediate target of
Wnt signalling and is an important regulator of the Wnt pathway.
The loss of Cited1 has a direct impact on stem cell status in the
small intestine as we have found several stem cell markers to be
upregulated including Lgr5 (Gpr49), Musashi and Olfm4. These
alterations in expression could be a direct consequence of the
‘hyper’ activation of the Wnt pathway we observe after combined
loss of Apc and Cited1. This would implicate Cited1 as an important
player in Wnt dependant stem cell maintenance in the small
intestine. This has been already suggested in the developing kidney
where Cited1 may contribute to the maintenance of the self-
renewing capping mesenchyme [18]. By regulating the Wnt
pathway, Cited1 may be an important regulator of the self-renewal
compartment in the crypt of the small intestine.
Our data show that Cited1 deficiency represses tumourigenesis.
The consequences of Cited1 deficiency are diverse, but in particular
impact upon Wnt pathway activity. We propose a model whereby
loss of Cited1, in the context of deregulated Wnt signaling, hyper-
activates the Wnt pathway resulting in apoptosis of Wnt induced
transformed cells and thus inhibits tumourigenesis. As Cited1 mice
are fertile and viable this suggests that Cited1 represents a possible
target for therapeutic intervention, where Cited1 inhibition
induces cytotoxic effects due to very high Wnt signalling.
Materials and Methods
Human colorectal cancer tissue RNA samples
Total RNA samples from patient colorectal tumour tissues were
obtained from the Cancer Tissue Bank Research Centre
(CTBRC). All colorectal cancer tissues and adjacent uninvolved
colonic mucosa were obtained from surgically removed specimens
with informed patient consent. Uninvolved colonic mucosa was
generally 5–10 cm away from the malignant tissue.
Mouse colonies
All experiments were performed under the UK Home Office
guidelines. Mice were obtained and genotyped as follows: Cited1
null (Cited12) [9]; ApcMin/+ [38]; AhCre transgene (AhCre+) [45];
Apc580S allele [46]; b-catfl/fl [47]; ApcMin/+ and ApcMin+Cited12 mice
were maintained on an inbred C57BL/6J background and were
confirmed as congenic for the C57BL/6 Mom-1 allele via PCR
analysis. Mice were sacrificed at ill-health. Intestine were fixed in
Methacarn (methanol-chloroform-glacial acetic acid [4:2:1]), and
the lesion numbers were scored macroscopically.
Figure 6. Level of the active form of b-catenin in the small intestine. A: Immunohistochemistry for total b-catenin in each genotype. Inset
panels show magnifications of intestine of corresponding zone. B: Small intestine epithelial cell extracts from AhCre+WT (WT; n = 14), AhCre+Cited12
(Cited12; n = 7); AhCre+Apcfl/fl (Apcfl/fl; n = 12); AhCre+Apcfl/flCited12 (Apcfl/flCited12) were analysed for the status of b-catenin using a suspension bead
array assay panel. Total b-catenin, dephospho b-catenin (S33, S37 and T41), phosphorylation at S33, S37, and T41, phosphorylation at S45,
phosphorylation at S552 and phosphorylation at S675 were analysed by using respective capture antibodies in multiplexed sandwich immunoassays.
Free b-catenin (non-complexed) was measured by mGST pull-down assays using GST-ICAT as bait protein. Signal intensities are displayed in relative
fluorescence units [AU] (mean+SE). *p,0.05; All statistical tests were done using Mann-Whitney U test. C:Western blot analysis of the Total form of b-
catenin in each genotype. The histogram represents the densitometry analysis of the total b-catenin immuno-blot normalised to the internal control
a-tubulin, showing an increase in the level of total b-catenin in AhCre+Apcfl/flCited12 (Apcfl/flCited12) compared to AhCre+Apcfl/fl(Apcfl/fl) and
AhCre+Cited12 also show an increase compare to AhCre+WT. D: Western blot analysis of the active form of b-catenin using dephospho-b-catenin
(dephosphorylated on Ser37/Thr41, Clone 8E7, Millipore) antibody in each genotype. The histogram represents the densitometry analysis of the
dephospho-b-catenin immuno-blot normalised to the internal control b-actin, showing an increase in the level of dephos-b-catenin in AhCre+Apcfl/fl
Cited12 (Apcfl/flCited12) compared to AhCre+Apcfl/fl(Apcfl/fl). The sample of each genotype is pooled from 3 to 7 mice in the cohort. AhCre+Apcfl/flb-catfl/fl
(Apcfl/flb-catfl/fl) is used as a negative control for dephospho-b-catenin.
doi:10.1371/journal.pgen.1003638.g006
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To study the role of Cited1 after the early loss of Apc, AhCre+WT,
AhCre+Apcfl/fl, AhCre+Cited12 and AhCre+Apcfl/flCited12 mice were
generated and maintained on an outbred background. Cre activity
was induced by three intraperitoneal injections of 80 mg/kg b-
naphthoflavone within 24 h and mice were taken Day4 or Day5
later. Tissues analysed were from age (8–12 weeks), sex (males),
background and genotype matched animals, however these were
not always littermates.
Assaying apoptosis, number of cells per crypt, S-phase
labelling in vivo and migration
Apoptosis was scored from H&E or after anti cleaved-Caspase3
immuno-staining as previously described [3]. For proliferation
analysis, mice were injected with 0.25 ml of BrdU (Amersham)
before culling and were taken either 2 hrs (day4) or 24 hrs (day5)
after BrdU injection. Staining was performed as previously
described [3]. The number of cells in AhCre+Apcfl/fl and
AhCre+Apcfl/flCited12 hyperplastic area was scored using the
position of the last BrdU positive cells in the hyperplastic area.
For each analysis, 25 full crypts or areas were scored from at least
3 mice of each genotype and time point.
In situ hybridization (ISH)
In situ hybridization of Olfm4 and Cited1 in the small intestine
was performed for all genotypes using sections embedded in
paraffin sectioned at 5 mm. Olfm4 hybridization was performed as
described in Gregorieff et al., 2005. [48]. Cited1 hybridization was
performed using a probe against the sequence deleted in the
Figure 7. Schematic diagram of a ‘‘just right’’ model of Cited1 action on colorectal tumourigenesis. Loss of function of Apc is
accompanied by multiple changes in gene expression, including upregulation of active b-catenin (dephospho-b-catenin), activation of Wnt and
Cited1. Hence, immediately following deletion of Apc, Cited1 normally restrains the Wnt pathway at the level of b-catenin. We observe a range of
rapid phenotypic changes. These include increase in proliferation and apoptosis and loss of differentiated cell types, also reduced migration, leading
to the preferential retention of Apc deficient cells. These changes may all be considered pro-tumourigenic, leading to survival advantage of the
tumour cell and decreased survival of the ApcMin/+ mouse compared to WT. Additional Cited1 deficiency leads to hyper-activation of Wnt signaling
including upregulation of active b-catenin and an exaggerated Wnt phenotype including elevated proliferation, a further loss of cell differentiation,
and most importantly increased cell death. The net effect of these changes is an increase in ApcMin/+ survival. This restraint imposed by Cited1 is
consistent with a requirement for Cited1 to constrain Wnt activity to a level commensurate with optimal adenoma formation and maintenance, and
provides one mechanism for tumour repression in the absence of Cited1.
doi:10.1371/journal.pgen.1003638.g007
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Cited12 allele designed by Advanced cell Diagnostics inc (ACD).
RNAscope 2.0 FFPE Reagent Kit – Brown kit was used according
manufacturer instructions. Negative control Probe-DapB was used
together with a positive control probe Polr2a from the ACD
manufacturer.
Microarray data analysis
The DNA microarray were performed from three mice of each
genotype using Mouse Genome 430 2.0 Affymetrix chips at
Liverpool Microarray Facility according to the manufacturer’s
instructions. The Microarray data were analyzed using Affylm-
GUI (Affymetrix linear modeling Graphical User Interface;
http://bioinf.wehi.edu.au/affylmGUI/#citation) [26]. The p
values presented have been corrected for multiple testing using
the BH method to control the false discovery rate. The B statistic is
the log odds that the gene is differentially expressed and is adjusted
for multiple testing using the assumption that 1% of genes are
expected to be differentially expressed [26,49–51]. Microarray
data were deposited in MIAME format at www.ebi.ac.uk/
arrayexpress/ (Accession Number: E-MEXP-3202)
QPCR protocols, routine methods and a description of the
statistical analyses used are provided in Protocol S1. List of
primers for Taqman RT-QPCR, Sybr green RT-QPCR, and
Cited1 semi quantitative RT-PCR are provided in Figure S4.
Analysis of signaling pathways
Ingenuity pathway analysis (IPA) software (www.ingenuity.com)
was used to determine which signaling pathways were affected by
the loss of Cited1 in AhCre+WT or AhCre+Apcfl/fl mice. The
comparative (AhCre+WT vs AhCre+Cited12 and AhCre+Apcfl/fl vs
AhCre+Apcfl/flCited12) data from the microarray analysis were
filtered for a p value of less than 0.05 and imported into the
IPA software. The significance of the association between the data
set and the pathway was measured in 2 ways: by the ratio and by a
p value. The ratio corresponds to the number of genes from our
data set that map to the ingenuity pathway divided by the total
number of genes that map to the Ingenuity canonical pathway.
The p value is calculated by a right tailed Fischer’s exact test. The
p-value associated with a pathway is a measure of the likelihood
that the association between a set of focus genes in your
experiment and a pathway is due to random chance.
b-catenin suspension bead array based assay
Analysis of biological function, localization, and posttransla-
tional modification of the different forms of b-catenin were carried
out as previously described [32]. Two additional assays were
included in the analysis. Anti-dephospho S33/S37 and T41 (Cell
Signalling Technologies) was used as an additional capture
antibody to measure dephosphorylated b-catenin and GST-ICAT
was employed as an additional bait protein to study free b-catenin.
Supporting Information
Figure S1 RT-PCR for Cited 1 expression in ApcMin/+ mice. A:
RT-PCR products showing up-regulation of Cited1 in polyps (T)
compared to normal intestinal tissue (N) in ApcMin/+. Note the
absence of RT-PCR products in ApcMin/+Cited12 condition
confirming the loss of Cited1 expression. b-actin was used as
internal positive control. B: RT-PCR of the Apc recombined
cDNA in AhCre+Apcfl/fl and AhCre+Apcfl/flCited12. The Apc non
recombined cDNA (wild type Apc) gives a band of 383 bp whereas
the Apc recombined cDNA (Apc Rec) gives a PCR product of
168 bp. C: Percentage tumour distribution varies in ApcMin/+ mice
compared to ApcMin/+Cited12 mice. The percentage tumour
distribution was analysed by counting tumour burden in each of
5 cm sections along the length of the small intestine and
representing this as a percentage of total tumour burden per
section. Sections 1–2 (duodenum), 3–5 (jejunum) 6–8 (comparable
to human Ileum). The colon was similarly divided into 1 cm
sections. Section 1 corresponding to the rectum. Error bars
represent standard errors. *p,0.05; statistical tests was done using
Mann-Whitney U test.
(TIF)
Figure S2 Increased level of dephosphorylated-b-catenin and
deregulated pathways in AhCre+Apcfl/flCited12 compared to Ah-
Cre+Apcfl/fl. A: Western blot analysis of the active form of b-catenin
(92 kD) using dephospho-b-catenin (Non-phospho-b-Catenin
Ser33/37/Thr41,Cell signalling) antibody in AhCre+WT (WT),
AhCre+Cited1 (Cited12), AhCre+Apcfl/fl (Apcfl/fl) and AhCre+Apcfl/fl
Cited12(Apcfl/flCited12). There is a strong up-regulation of depho-
spho-b-catenin in AhCre+Apcfl/fl compared to AhCre+WT and
AhCre+Cited12 and the level of dephospho-b-catenin is further
elevated in AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl. B: The
histogram represents the densitometry analysis of the dephospho-
b-catenin immumo-blot normalised to the internal control b-actin.
AhCre+Apcfl/flBeta-catfl/fl (Apcfl/flBeta-catfl/fl) is used as a negative
control. C: A: Fold change of target genes expression (other than
Wnt) in the small intestinal epithelium of AhCre+Apcfl/flCited12
compared to AhCre+Apcfl/fl mice measured by QRT-PCR, *p,0.05
Mann Whitney U test. D: Microarray analysis showing up-
regulation of Wnt target genes with Wnt Key players in AhCre+WT
compared to AhCre+Cited12 and AhCre+Apcfl/fl compared to
AhCre+WT: Fold changes (FC) are presented with correspondent
P value and B value (B statistic is lod score).
(TIF)
Figure S3 Cited1 deficiency does not modify the renal carcinoma
phenotype induced after loss of Apc and activation of K-rasV12. Cre
recombinase under the Cyp1A promoter has also been shown to
be constitutively expressed in a proportion of cells in the renal
epithelium [reference S1, in Protocd S1]. This drives loss of the
Apc allele and the formation of dysplastic foci characterised by
accumulation of nuclear b-catenin. Within 4 months, mice
develop renal carcinoma [reference S1, in Protocd S1] which
can be accelerated by an additional K-rasV12 oncogene [reference
S2, in Protocd S1]. To study the role of Cited1 in renal cell
carcinoma, mice AhCre+Apcfl/fl K-rasV12, AhCre+Apcfl/fl K-ras-V12
Cited2/+ and AhCre+Apcfl/fl K-ras-V12Cited12 were generated and
maintained on an outbred background. All experiments were
performed under the UK Home Office guidelines. K-rasV12 allele
was obtained and genotyped as previously described [reference S3,
in Protocd S1]. Mice were sacrificed at ill health. We analysed
expression of Cited1 in the renal carcinomas of AhCre+Apcfl/flK-
rasV12 compared to normal tissue. Histograms (A) are showing
qRT-PCR delta CT values (left panel) and Fold change (right
panel) for Cited1 expression in the kidneys of AhCre+WT,
AhCre+Apcfl/fl K-rasV12 (tumours) and AhCre+Apcfl/flK-rasv12Cited12
(tumours) mice. There is a significant 19.48 fold increase in Cited1
expression in AhCre+Apcfl/flK-rasV12 mice kidneys compared to WT
mice (p = 0.0041 Mann-Whitney U test) and 1007 fold change
difference between AhCre+Apcfl/flK-rasV12 and AhCre+Apcfl/flK-rasV12-
Cited12 (p = 0.0071 Mann-Whitney U test). (B) We generated
cohorts of AhCre+Apcfl/flK-rasV12, AhCre+Apcfl/flK-rasV12Cited12 and
AhCre+Apcfl/flK-rasV12Cited12/+ mice and monitored them for signs
of illness. The Kaplan-Meier shows no significant difference in
survival between AhCre+Apcfl/flK-rasV12 mice (n= 13) (dashed) versus
AhCre+Apcfl/flK-rasv12Cited12 (n = 4) (Bold solid line; p = 0.732, Log-
Rank test) and between AhCre+Apcfl/flK-rasv12 versus AhCre+Apcfl/flK-
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rasV12Cited12/+ (n = 5) (Thin solid line; p = 0.555 Log-Rank test).
The median lifespan was 88 days in AhCre+Apcfl/flK-rasV12 (n = 13),
72 days in AhCre+Apcfl/flK-rasV12Cited12 (n = 4) and 81 days in
AhCre+Apcfl/flK-rasV12Cited12/+ (AhCre+Apcfl/flK-rasV12 vs AhCre+Apcfl/
flK-rasV12Cited12, Log Rank p= 0.732; AhCre+Apcfl/flK-rasV12 vs
AhCre+Apcfl/flK-rasV12Cited12/+ Log Rank p= 0.555). These data
indicate that Cited1 deficiency does not modify the survival of mice
affected by renal carcinoma and that Cited1 does not play a role in
renal carcinoma induced by a loss of Apc.
(TIF)
Figure S4 Primers Table. Tables listing the primers and probes
used for Taqman quantitative PCR in human (A) and in mice (B);
Sybr Green quantitative real time PCR in mice (C) and semi-
quantitative PCR in mice (D).
(TIF)
Figure S5 Cited1 deficiency further represses the number of
differentiated cell types after Apc loss. To determine if deficiency
of Cited1 modifies cell differentiation along the crypt-villus axis, we
analysed the presence and location of several secretory cell types
using markers of cell lineage in mice intestinal epithelium of all 4
genotypes: goblet cells (A–B) (Alcian Blue staining and counting),
enteroendocrine cells (C–D) (Grimelius staining and counting) and
paneth cell (E–F) (Lysozyme staining and counting). (G) Paneth
cells position was analysed. Goblet cells and enteroendocrine cells
were scored in 25 crypts (or hyperplastic areas)-villus (n = 6/
genotype) (All statistical analysis were done using the Mann-
Whitney U test and NS=Non significant). We found that the
number of goblet cells and enteroendocrine cells were not
significantly different in AhCre+WT mice compared to AhCre+-
Cited12 mice (Goblet cells =AhCre+WT: 9.8 cells/crypt-villus vs
AhCre+Cited12: 11.4 cells/crypt-villus, p = 0.1312, ; Enteroendo-
crine cells =AhCre+WT: 1.56 cells/crypt-villus vs AhCre+Cited12:
1.61 cells/crypt-villus, p = 0.5) (B,D). However, the number of
goblet cells and enteroendocrine cells per hyperplastic area-villus
were both significantly reduced in AhCre+Apcfl/flCited12 mice
compared to AhCre+Apcfl/fl mice (Goblet cells =AhCre+Apcfl/fl :
5.26 cells/area-villus vs AhCre+Apcfl/flCited12: 3.71 cells/area-villus,
p = 0.0463, Enteroendocrine cells =AhCre+Apcfl/fl: 1.04 cells/area-
villus vs AhCre+Apcfl/flCited12: 0.73 cells/area-villus, p = 0.0125)
(B,D). The position and the number of paneth cells are not
modified in AhCre+Cited12 mice compared to AhCre+WT mice (E–
G). After loss of Apc, paneth cells lose their position at the bottom
of the crypt and are mislocalised along the crypt-villus axis (G). We
observe a change in position of the paneth cells in the hyperplastic
areas of the AhCre+Apcfl/flCited12 compared to AhCre+Apcfl/fl (E–G).
Statistical test was done using Kolmogorov–Smirnov test (G). Inset
panels show magnifications of intestine of corresponding zone.
Taken altogether, these data suggest that loss of Cited1 does not
perturb the pattern of differentiation when Apc is present. However
in the absence of Apc, Cited1 deficiency appears to accentuate the
phenotype, with a more extreme reduction in the number of
differentiated cell types.
(TIF)
Protocol S1 Statistical Analysis, Quantitative real-time PCR
on mice samples, Cited1 status by Semi-quantitative PCR, First
strand cDNA synthesis and taqman quantitative qPCR on
human samples, Western Blot analysis, RNA and protein
isolation from mice small intestine, Histology and Immunohis-
tochemistry and Supplementary references are provided as
supplementary informations. Primers list for Taqman RT-
QPCR, Sybr green RT-QPCR and semi quantitative RT-PCR
are listed in Figure S4.
(DOC)
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